At the forefront of lung 癌症 treatment
首页 / 澳门葡京赌博游戏的治疗领域 / 肿瘤学 /肺癌
Lung 癌症 is the leading cause of 癌症 death worldwide, accounting for about 2.2 million patients diagnosed and 1.8 million deaths each year.1 The two main types of lung 癌症 are non-small cell lung 癌症 (NSCLC), which represents 80-85% of patients, and small cell lung 癌症 (SCLC), the more aggressive and fast-growing 癌症 type, representing about 15% of patients.2-3
The earlier we can detect and treat lung 癌症, the closer we are to cure.4-5 Unfortunately, early diagnosis is not always a reality.6
lung="" (nsclc),="" (sclc),="" 1.8="" 15%="" 2.2="" 80-85%="" about="" accounting="" aggressive="" and="" are="" 癌症="" cause="" cell="" death="" deaths="" diagnosed="" each="" fast-growing="" for="" h3="" is="" leading="" lung="" main="" million="" more="" non-small="" of="" patients="" patients,="" patients.2-3<="" representing="" represents="" small="" style="margin-left: -.25in;" the="" two="" type="" types="" which="" worldwide,="" year.1 the="">
在很多情况下, lung 癌症 goes undetected until it is in advanced stages or the 癌症 comes back after initial treatment.6 For these patients who experience recurrence, outcomes are especially poor.4-5 To meaningfully improve outcomes, we are prioritising lung 癌症 research to increase early screening and diagnosis and address the significant unmet need for treatments at every stage of the disease continuum.
澳门葡京赌博游戏的方法
Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action.7 澳门葡京赌博游戏的方法 is driven by precision medicine, using groundbreaking science to further our understanding of lung 癌症 and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung 癌症, from early stages – where we aim to help patients live longer and 癌症-free – to late stages, where we look to meaningfully extend survival.
Our scientific platforms
Tumour drivers and resistance (TDR)
We are defining new biomarkers and therapeutic targets to transform the way lung 癌症 is diagnosed and treated. Our research has led us to address the unmet needs of patients with mutations in the epidermal growth factor receptor (EGFR). We are also investigating resistance mechanisms and emerging biomarkers, such as alterations in the MET gene, to help answer what comes next for patients whose 癌症 progresses despite treatment with today’s standard-of-care therapies.
Antibody drug conjugates (ADCs)
We are investigating antibody drug conjugates (ADCs) to target actionable biomarkers such as human epidermal growth factor 2 (HER2). Un就像 conventional chemotherapy treatments which can damage healthy cells, ADCs can deliver a 癌症 drug directly into 癌症 cells to reduce damage caused to healthy cells. 目前, patients whose tumours express HER2 and who have progressed after treatment have limited options, as there are no available HER2 directed medicines approved in NSCLC.
Immuno-oncology (IO)
Immunotherapies are designed to target immune checkpoints that are exploited by 癌症 to avoid or suppress the immune system’s ability to recognise and destroy 癌症 cells. Across our clinical trials, we are testing IO as monotherapy (by itself) and also in combinations with chemotherapy, 小分子, antibody drug conjugates and other immunotherapies across multiple tumour types, stages of disease and lines of treatment.
Advancing treatments through innovative trial design
While many new treatments have focused on advancing care for metastatic patients with a high unmet medical need, we prioritised pushing treatment into earlier lung 癌症 settings. To really cure 癌症, we need to treat earlier to maximise the potential for long-term disease remission and the possibility of cure.6 In pursuit of this goal, we have launched more than a dozen Phase II and III clinical trials evaluating our Immuno-肿瘤学 and gene-targeted therapies in earlier stages of disease.7 In the Immuno-肿瘤学 space alone, we now lead with the largest proportion of Phase III trials in early disease across the industry, with many ongoing across the NSCLC and SCLC settings.7
Downloadable infographics
Changing the pace of progress in lung 癌症 survival
As a founding member of the Lung Ambition Alliance, a partnership of organisations driving forward meaningful improvements for people with lung 癌症, we have the ambitious goal to eliminate lung 癌症 as a cause of death. To meet this goal, the Alliance advocates for improved approaches in three key areas –
1. Increasing screening rates and diagnostic testing.
2. Accelerating the delivery of innovative medicine.
3. Improving quality of care.
Recent and ongoing initiatives include policy reports, 就像 Lung Cancer 筛选: The Cost of Inaction which outlines the opportunity presented by lung 癌症 screening to reduce costs while saving lives; strategic global, regional and local collaborations, 就像 爱的人 using artificial intelligence to improve early lung 癌症 diagnoses; the ILC2 补助计划 which funds non-profit initiatives with transformative potential for patient care; and efforts to study oncology endpoints to accelerate drug approvals in earlier settings of lung 癌症.8
Other key disease areas
加入澳门葡京赌博游戏
We are driven by our passion, our people and a culture of innovation. 澳门葡京赌博游戏重视勇气, 好奇心, collaboration and passion for learning, and we encourage disruptive thinking where failure is an opportunity to learn – the freedom to take risks without fear of failure.
澳门葡京赌博游戏的人民
“I am passionate about developing medicines to improve the outcomes for patients with 癌症 and developing the skills and experience of the people within my team" Susan Galbraith, Executive Vice-President, 肿瘤学 R&D
参考文献
- World Health Organization. Globocan 2020 Fact Sheet. Available at: http://gco.研究.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed September 2021.
- American Cancer Society. What is Lung Cancer? Available at: http://www.癌症.org/癌症/lung-癌症/about/what-is.html. Accessed September 2021.
- National Cancer Institute. NCI Dictionary - Small Cell Lung Cancer. Available at: http://www.癌症.gov/publications/dictionaries/癌症-terms/def/small-cell-lung-癌症. Accessed September 2021.
- ASCO. Lung Cancer - Small Cell. Available at: http://www.癌症.net/癌症-types/33776/view-all. Accessed September 2021.
- ASCO. Lung Cancer - Non-Small Cell. Available at: http://www.癌症.net/癌症-types/lung-癌症/view-all. Accessed September 2021.
- LUNGevity Foundation. 筛选 & 早期检测. Available at: http://lungevity.org/for-patients-caregivers/lung-癌症-101/screening-early-detection. Accessed September 2021.
- 澳门葡京网赌游戏. Clinical trials appendix. H1 2021 results update. Available at: http://www.AstraZeneca PLC.com/content/dam/az/PDF/2021/h1-2021/H1_2021_results_clinical_trials_appendix.pdf. Accessed September 2021.
- Lung Ambition Alliance. Available at: http://www.lungambitionalliance.com. Accessed September 2021.